1
THE 19thTEL-AVIVUNIVERSITY ALZHEIMER'S DISEASE CONFERENCE
Sponsored by the AdamsSuperCenter for Brain Studies and
The RabinCenter for Neurobiology.
Tel-AvivUniversity
June15-16, 2011
Program
WEDNESDAY, JUNE 15, 2011
Lectures will be held at the Tel-AvivUniversity Campus, Faculty of Life Sciences, Hall 14
08:00–08:30Registration
Chair: Amos Korczyn and Danny Michaelson
08:30 - 08:40Greetings: Illana Gozes, Geri Rot
Diabetes and Alzheimer’s disease
Chair: Elissa Ash, Jonathan Streifler
08:40 – 09:10Deborah Gustafson Epidemiology of type II diabetes and dementia
09:10 – 09:40 Jose Luchsinger Diabetes and related conditions: from observation to
translation
09:40 – 10:00 Tali Cukierman-Yaffee The hypoglycemia-cognition relationship - what is the
direction?
10:00 – 10:20 Michal Beeri Diabetes characteristics and cognitive performance
10:20 – 10:40 Illana Gozes Functional and structural protection against cognitive
dysfunctionin a diabetes model by the clinical stage drug
candidate NAP (davuntide)
10:40 – 11:10Coffee break
AD pathology
Chair: Haim Belmaker, Mona Soreq
11:10 – 11:30Reuven SteinPresenilin 1 regulates the expression of the transcriptional
coactivator PGC-1α via the intracellular domain of APP:
implications for mitochondrial energy metabolism
11:30 – 11:50Joab Chapman The role of thrombin in neurodegeneration: Resultsfrom models of trauma
and diabetes
11:50 - 12:10 Amit Berson Micro RNA mediated alternative splicing impairments in Alzheimer’s
disease
12:10 – 12:30Alon Monsonego Do we care about Aβ plaques in Alzheimer’s disease?
12:30 – 12:50 Dan FrenkelInsulin degrading enzyme deficiency accelerates
cerebrovascular amyloidosis in an animal model
12:50 - 13:10Dan KaganovichSpatial organization of protein folding quality control
13:10 – 14:10Lunch
AD therapy and treatment
Session in honor of the late Mrs. Miryam Lebach
Chair: John Finberg, Veronika Vakhapov
14:10– 14:30 Abraham Fisher A comprehensive mono-therapeutic strategy against Alzheimer's
disease, Parkinson's disease and Dementia of Lewy Bodies
14:30 – 14:50 Henry Silver Executive impairments in healthy aging are selective –
implications for studies of dementia
14:50 - 15:10 Ariela AlterSignificant cognitive function improvement following treatment
of AD patients with the NICE de
15:10 – 15:30 Moran Frenkel Pinter The drosopila eye as a model for neurodegeneration and drug
screening
15:30– 15:50Coffee break
AD therapy and treatment (Cont.)
Chair: Ed Stern, Daniel Offen
15:50 – 16:10 Rene Spiegel Substituting placebo controls in long-term Alzheimer prevention
trials: The placebo group simulation approach (PGSA)
16:10– 16:30 Jacobson/Inbal- Kariv Prevention of the pathological effects of apoE4 by DHA
16:30 – 16:50 Yoram Barak Escitalopram versus risperidone for the treatment of BPSD in
Alzheimer’s disease
16:50 - 17:10Ramit Ravona Motivation to change status at work during midlife and risk
fordementia at old age
THURSDAY, JUNE 16, 2011
Lectures will be held at the Tel-AvivUniversity Campus, Faculty of Life Sciences, Hall 14
The Eye and Alzheimer’s disease
Session in honor of the late Mr. Joseph and Mrs. Inez Eichenbaum
Chair: Dov Weinberger, Judith Aharon
08:40 – 09:00Ayalla Pollack AMD and Alzheimer’s disease
09:00–09:20ShimonKurtz Glaucoma and Alzheimer’s disease
09:20 – 09:40 Anat Kesler Optic nerve and retinal nerve fiber layer changes in Alzheimer ‘s
and other neurodegenerative diseases
09:40 – 10:00Arieh Solomon The eye in non-invasive early detection of AD
10:00– 10:20 Ron Ofri Preventing optic neuropathy in animal models of glaucoma
10:20– 10:40 Michal Schwartz “The eyes are the window of the soul” – implications for
neurodegenerative disorders
.
10:40 – 11:10Coffee break
Vascular inflammatory factors
Session in honor of the late Mrs Leah Superstein
Chair: Silvia Mandel, Tzvi Dwolatzky
11:10 – 11:30Ari BarzilaiA role for vascular and glial deficiencies in retinal pathology in a
mouse model of ataxia-telangiectasia
11:30– 11:50Antes/ Maharshak The effects of ApoE4 on retinal neuronal and vascular
systems
11:50 – 12:10Sigal FleisherRegulation of microglial functions by neuropeptides : Possible
implications for Alzheimer’s disease
12:10 – 12:30Luz/Frenkel The role of VEGF inmediating the effects of ApoE4
12:30 – 12:50 Einor Ben–Assayag Inflammatory markers, hippocampal volume and cognitive
performance in stroke patients
12:50 – 13:10 Aharon Buchman Motor decline in preclinical Alzheimer’s disease
13:10 – 14:10Lunch
Mechanisms underlying dementia
Session in honor of the late Professor Max Streifler
Chair : Eli Wertman, Michael Davidson
14:10 – 14:30Neil Kowall Does microvascular disease cause Alzheimer-type neuropathology?
14:30 – 14:50Uri Goldbourt Non-HDL cholesterol coronary artery disease, mortality and late life
dementia
14:50 – 15:10Shahar Barbash Dynamics of shifts in functional gene groups along Alzheimer’s disease
progression
15:10 – 15:30Coffee break
15:30 - 17:00 Round table:Aβ: The good, the bad and the ugly
Chair: Amos Korczyn and Danny Michaelson